An Open-label Phase Ib/II Study of Avelumab in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Avelumab (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 21 Feb 2017 Planned End Date changed from 1 Mar 2020 to 1 Feb 2020.
- 21 Feb 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Feb 2020.
- 21 Feb 2017 Status changed from not yet recruiting to recruiting.